Proteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus

dc.contributor.authorGay, Marina
dc.contributor.authorParés Darnaculleta, Albert
dc.contributor.authorCarrascal Pérez, Montserrat
dc.contributor.authorBosch i Crespo, Pau
dc.contributor.authorGorga, Marina
dc.contributor.authorMas, Antoni
dc.contributor.authorAbián, Joaquín
dc.date.accessioned2016-03-03T10:43:56Z
dc.date.available2016-03-03T10:43:56Z
dc.date.issued2011-07-14
dc.date.updated2016-03-03T10:44:01Z
dc.description.abstractAlbumin dialysis using the molecular adsorbent recirculating system (MARS) is a new therapeutic approach for liver diseases. To gain insight into the mechanisms involved in albumin dialysis, we analyzed the peptides and proteins absorbed into the MARS strong anion exchange (SAX) cartridges as a result of the treatment of patients with cholestasis and resistant pruritus. Proteins extracted from the SAX MARS cartridges after patient treatment were digested with two enzymes. The resulting peptides were analyzed by multidimensional liquid chromatography coupled to tandem mass spectrometry. We identified over 1,500 peptide sequences corresponding to 144 proteins. In addition to the proteins that are present in control albumin-derived samples, this collection includes 60 proteins that were specific to samples obtained after patient treatment. Five of these proteins (neutrophil defensin 1 [HNP-1], secreted Ly-6/uPAR-related protein 1 [SLURP1], serum amyloid A, fibrinogen alpha chain and pancreatic prohormone) were confirmed to be removed by the dialysis procedure using targeted selected-reaction monitoring MS/MS. Furthermore, capture of HNP-1 and SLURP1 was also validated by Western blot. Interestingly, further analyses of SLURP1 in serum indicated that this protein was 3-fold higher in cholestatic patients than in controls. Proteins captured by MARS share certain structural and biological characteristics, and some of them have important biological functions. Therefore, their removal could be related either to therapeutic or possible adverse effects associated with albumin dialysis.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec609291
dc.identifier.issn1932-6203
dc.identifier.pmid21779339
dc.identifier.urihttps://hdl.handle.net/2445/96082
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0021850
dc.relation.ispartofPLoS One, 2011, vol. 6, num. 7, p. e21850
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0021850
dc.rightscc-by (c) Gay, M. et al., 2011
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties del fetge
dc.subject.classificationAlbúmines
dc.subject.classificationColèstasi
dc.subject.classificationDiàlisi
dc.subject.otherLiver diseases
dc.subject.otherAlbumins
dc.subject.otherCholestasis
dc.subject.otherDialysis
dc.titleProteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
609291.pdf
Mida:
285.05 KB
Format:
Adobe Portable Document Format